BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest ...

Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

There will be another ‘COVID’. Governments are planning for it, but how coordinated is that planning, and how resilient will ...

AN Venture Partners has closed its first fund, a $200 million vault for biotechs worldwide, with particular emphasis on ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.